Pulmonary Edema - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pulmonary edema market size is projected to expand from USD 7.41 billion in 2025 and USD 7.91 billion in 2026 to USD 11.32 billion by 2031, registering a CAGR of 7.43% between 2026 to 2031. This report is Segmented by Type (Cardiogenic, Non-Cardiogenic, High-Altitude, Infection-Induced), Treatment and Diagnosis Method (Treatment [Diuretics, Oxygen Therapy, Mechanical Ventilation, Vasodilators], Diagnosis [X-Ray, CT, Ultrasound, Echocardiography, Biomarkers]), End Use (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Value (USD).

Global Pulmonary Edema Market Trends and Insights

Aging Heart Failure and Valvular Disease Burden

The pulmonary edema market continues to draw core demand from the expanding heart failure population, especially among older adults who are more exposed to congestion-related hospital episodes. Data from the PORTHOS study showed heart failure prevalence at 16.5% among adults aged 50 and above in Portugal, and 30.7% among those aged 70 and above, which points to the scale of age-linked risk that supports this market over time. The pulmonary edema market is also supported by the large number of patients living with structurally weakened left ventricles and recurrent fluid overload risk after surviving serious cardiac events. In July 2025, Bayer received FDA approval for finerenone in patients with heart failure and left ventricular ejection fraction of 40% or more, opening treatment access for a large population that had previously faced limited guideline-directed options. That approval strengthens the therapeutic base of the pulmonary edema market because pulmonary congestion management is closely tied to the broader expansion of treated heart failure care.

Wider Use of Point-of-Care Lung Ultrasound and BNP Triage

The pulmonary edema market is seeing faster diagnostic movement as point-of-care lung ultrasound becomes more established in emergency assessment of acute dyspnea. A 2025 prospective study found that lung ultrasound delivered results in a median of 10.0 minutes compared with 62.5 minutes for chest X-ray, which supports quicker clinical decisions when pulmonary congestion is suspected. A multicenter French study also showed that combined lung and focused cardiac ultrasound performed better than NT-proBNP alone for diagnosing acute left heart failure in patients aged 75 and above. This is important for the pulmonary edema market because a more reliable first-line triage pathway can raise confidence in early intervention while also sending unclear cases toward higher-value confirmatory imaging. AI-assisted B-line quantification is adding another layer to the pulmonary edema market by helping ultrasound platforms move beyond basic imaging into software-supported decision-making.

Diagnostic Overlap With COPD, Pneumonia, and Mixed Etiologies

The pulmonary edema market still faces a major clinical barrier because overlap with COPD, pneumonia, and mixed respiratory presentations can delay the right treatment decision. A 2025 study reported that 38% of patients with confirmed COPD on optimal GOLD-guided therapy were later found to have undiagnosed heart failure, which shows how often fluid overload can stay hidden inside established respiratory case pools. Biomarkers and imaging do not always solve this problem quickly, because NT-proBNP may rise outside true congestion states, and chest imaging can show overlapping signs across pulmonary infection and edema. The pulmonary edema market, therefore, loses some momentum when clinicians cannot confidently separate cardiac and pulmonary causes during the first evaluation window. A 2025 study in iScience showed that an AI-assisted XGBoost model sharply improved the separation of acute COPD exacerbation from acute heart failure, which suggests that better software tools could ease this restraint over time.

Other drivers and restraints analyzed in the detailed report include:

• Growth in Non-Invasive Ventilation Across Emergency and Critical Care Pathways
• AI-Enabled Radiology Triage and ED Workflow Integration
• Safety Limits of Aggressive Diuresis and Vasodilator Use

Segment Analysis

Cardiogenic pulmonary edema held 41.67% of revenue in 2025, giving it the largest position within the pulmonary edema market by type. This leadership reflects the persistent burden of left ventricular dysfunction, valvular disease, and hypertensive crisis in hospitalized populations. The pulmonary edema market remains anchored to these conditions because acute decompensation episodes continue to require rapid treatment and monitoring in structured care settings. Finerenone added a new element to this segment when Bayer secured FDA approval in July 2025 for heart failure patients with a left ventricular ejection fraction of 40% or more. That move widens the treatment framework around congestion management and supports the cardiogenic side of the pulmonary edema market with a clearer pharmaceutical pathway.

The same segment also shows why leadership does not fully define future growth in the pulmonary edema market. Non-cardiogenic pulmonary edema is forecast to grow at a 9.15% CAGR through 2031, making it the fastest-growing type segment. That pace reflects rising clinical focus on sepsis-associated lung injury and other permeability-driven cases that do not respond to care models built only around fluid removal. A 2025 review in Frontiers in Medicine reported ICU mortality of 35% to 46% among ARDS patients, where sepsis is the leading cause, which keeps clinical urgency high around this subtype. As a result, the pulmonary edema industry is moving toward a wider treatment lens in which non-cardiogenic disease forms matter more for pipeline positioning, ICU protocols, and future investment decisions.

Complete Report Scope:

• By Type
  • Cardiogenic Pulmonary Edema
  • Non-Cardiogenic Pulmonary Edema
  • High-Altitude Pulmonary Edema
  • Pulmonary Edema Due to Infection
• By Treatment & Diagnosis Method
  • Treatment
    • Diuretics
    • Oxygen Therapy
    • Mechanical Ventilation
    • Pulmonary Vasodilators
  • Diagnosis Method
    • Chest X-Ray
    • Computed Tomography
    • Lung Ultrasound
    • Echocardiography
    • Blood Biomarkers
• By End Use
  • Hospitals
  • Home Healthcare Settings
  • Ambulatory Surgical Centers
  • Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.03% of revenue in 2025, which made it the largest regional component of the pulmonary edema market. The region benefits from a large treated heart failure population and a care system that supports both branded therapy adoption and advanced diagnostics. A 2025 review noted that 6.7 million Americans aged 20 and above were living with heart failure, and that total is projected to rise to 8.5 million by 2030, which gives the pulmonary edema market a broad and recurring patient base. The United States also has financing structures that place pressure on costly admissions while rewarding better chronic management, which supports interest in home monitoring and outpatient congestion control. Europe remains another major pillar of the pulmonary edema market because Germany, France, the United Kingdom, and Italy maintain strong guideline-driven care pathways for acute heart failure, respiratory support, and biomarker-led triage. In March 2026, Bayer received European Commission approval and UK authorization for finerenone in adults with heart failure and left ventricular ejection fraction of 40% or more, which expanded a meaningful treatment opportunity across regional care systems.

Asia-Pacific is forecast to grow at a 9.01% CAGR through 2031, giving it the fastest regional expansion in the pulmonary edema market. Growth in the region is supported by hospital capacity expansion, wider awareness of acute decompensated heart failure, and the rising use of imaging-led diagnosis in major urban centers. The pulmonary edema market is also gaining support from broader digital adoption, including AI-based chest imaging validation work conducted across Indian clinical sites. A 2026 study in the International Journal of Research in Medical Sciences reported strong validation performance for the Lenek intelligent radiology assistant in screening and triage of pulmonary and cardiac conditions across India. That kind of deployment matters for the pulmonary edema market because it can improve triage in health systems that face high patient volumes and uneven specialist access. The region’s scale and infrastructure growth keep Asia-Pacific central to the next phase of expansion.

Middle East & Africa and South America remain smaller contributors to the pulmonary edema market, but both regions are building relevance through critical care and diagnostic capacity improvements. GCC countries are investing in hospital modernization, ventilator procurement, and echocardiography access, which supports gradual uptake of higher-acuity pulmonary care pathways. In South America, Brazil and Argentina continue to anchor demand where metropolitan hospitals are better positioned to adopt structured edema diagnosis and treatment protocols. These regions still face uneven access and slower rollout outside leading urban systems, but the pulmonary edema market is gaining a more stable base as post-crisis ICU investment strengthens referral and treatment capabilities.

List of Companies Covered in this Report:

• Abbvie
• Argon Medical Devices
• AstraZeneca
• Baxter
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Edward Lifesciences
• Eli Lilly and Company
• Fresenius
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Johnson & Johnson
• Lupin
• Merck
• Novartis
• Pfizer
• Roche
• Sanofi
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support